Clovis Oncology receives Breakthrough Therapy designation for Rubraca

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More

Tuesday October 2, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, FDA

Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA

Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI),... Read More

Tuesday August 7, 2018 0 comments Tags: Boulder, Array BioPharma, Victor Sandor, FDA

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More

Monday July 16, 2018 0 comments Tags: Boulder, Array BioPharma, melanoma, Ron Squarer, FDA

Fischer Medical receives FDA clearance to market Bloom2 cardiac stimulator

Fischer Medical receives FDA clearance to market Bloom2 cardiac stimulator

WHEAT RIDGE -- Fischer Medical announced its Bloom2 cardiac electrophysiology stimulator device has received U.S. Food and Drug Administration 510(k) clearance. The Bloom2 stimulator is a... Read More

Tuesday April 10, 2018 0 comments Tags: Wheat Ridge, Fischer Medical, Bloom2, FDA, Wes Rogers

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More

Tuesday October 10, 2017 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey, FDA

InDevR licenses FDA influenza antibodies for VaxArray potency platform

InDevR licenses FDA influenza antibodies for VaxArray potency platform

BOULDER -- InDevR , a Boulder-based progressive analytical technology and life science instrumentation company, today announced it has entered into an agreement to license monoclonal antibodies... Read More

Tuesday January 17, 2017 0 comments Tags: Boulder, InDevR, FDA, VaxArray, Dr.Kathy Rowlen, influenza

Ampio: FDA discussions continue on best path forward for Ampion

Ampio: FDA discussions continue on best path forward for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it is continuing discussions with the CBER Division of the FDA to determine the best path forward to obtain a Biological... Read More

Thursday November 10, 2016 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA

Taiga Biotechnologies awarded Orphan Drug Designation for experimental stem therapy

Taiga Biotechnologies awarded Orphan Drug Designation for experimental stem therapy

AURORA -- The Food and Drug Administration (FDA) has given Taiga Biotechnologies Inc. Orphan Drug Designation for an experimental product designed to treat children with a rare immune deficiency... Read More

Tuesday June 14, 2016 0 comments Tags: Aurora, Taiga Biotechnologies, Brian Turner, TBX-1400, FDA, Yosef Refaeli